H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on Arcellx to $50 from $49 and keeps a Buy rating on the shares post the Q2 report. The partial clinical hold for CART-ddBCMA announced on June 19 has been lifted by the FDA ahead of expectations, the analyst tells investors in a research note. The firm expects the shares to trade up on the news.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACLX:
- Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results
- Arcellx announces FDA lifted clinical hold for iMMagine-1 Phase 2 program
- Arcellx reports Q2 EPS (50c), consensus (31c)
- Is ACLX a Buy, Before Earnings?
- Arcellx hold doesn’t decrease William Blair confidence in CART-ddBCMA